📖 8 min read🔬 Research & Education⚠️ Not medical advice✅ Last reviewed: April 2026
Educational research only. The compounds discussed here are not approved by the FDA, EMA, MHRA, TGA, or Health Canada for human therapeutic use. They are research chemicals. Nothing on this page is medical advice. You must be 18+. Consult a licensed healthcare professional before acting on anything you read. Full disclaimer →
Reviewed by: WolveStack Research Team
Last reviewed: 2026-04-28
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Quick Answer: MK-677 (ibutamoren / Nutrobal) is Merck's oral non-peptide growth hormone secretagogue from the 1990s — works on the same ghrelin receptor (GHSR-1a) as ipamorelin but as a small molecule with >60% oral bioavailability. Nass et al. (2008) demonstrated 1.
What is MK-677?
MK-677 (also called ibutamoren or Nutrobal) is the GH secretagogue that almost made it through approval, then didn't. Merck developed it in the 1990s as a non-peptide oral compound — most growth hormone secretagogues are peptides that need injection, but MK-677 mimics ghrelin signaling well enough to be effective orally. Multiple Phase II/III trials in sarcopenia, hip fracture recovery, and growth hormone deficiency. The reason it never crossed the regulatory finish line wasn't safety in any catastrophic sense — it was the predictable consequences of long-term GH elevation: weight gain, fluid retention, modest blood sugar deterioration. Merck called it. Reverse Pharma (a Merck spinoff) continued partial development without approval success.
Mechanism
MK-677 is a non-peptide ghrelin receptor (GHSR-1a) agonist — same receptor as ipamorelin, completely different molecule class. Oral bioavailability is >60%, which is unusual for ghrelin pathway agents. Half-life is ~4-6 hours, but the downstream effects last much longer because of receptor signaling dynamics — once-daily dosing is sufficient. Long-term use elevates IGF-1 by 60-90%, which is a substantial steady-state shift. The pulsatility is somewhat preserved (unlike CJC-1295 with DAC), which is part of why the cardiovascular and metabolic side effect profile is more manageable.
Research Evidence
The single most important MK-677 paper is Nass et al. (2008) in the Annals of Internal Medicine — a 2-year study in healthy older adults (65+) showing 1.6 kg lean mass gain, modest bone density improvement (+0.7%), and 60% IGF-1 elevation. Murphy et al. (1998) demonstrated GH pulse restoration in adult GH-deficient patients. The hip fracture recovery trial (Adunsky et al., 2011) didn't hit primary endpoints, which contributed to Merck's decision to stop development. The long-term Nass data is what most informs current research dosing protocols.
Dosing Considerations
Research protocols use 10-25 mg orally once daily. Doses above 25 mg don't show additional benefit — IGF-1 elevation plateaus. Pre-bed dosing aligns with natural GH pulse timing and tends to produce the strongest IGF-1 response. Empty stomach (30+ minutes before food) may modestly improve absorption but the effect isn't dramatic. Cycling is debatable — some research protocols cycle 8-12 weeks on, 4 weeks off; others run continuously based on the long-term Nass safety data.
Safety
Side effects: appetite increase (60-70% of users — that's the ghrelin signaling), sodium and water retention (most pronounced in the first 2-4 weeks, generally improves), occasional transient muscle aches, modest glucose tolerance deterioration (HbA1c +0.1-0.2% in the Nass trial). Insulin resistance is the main long-term concern — pre-diabetics and diabetics should be cautious or avoid. CHF decompensation showed up in some trials, so heart failure is a contraindication. WADA banned (S2 class), so competitive athletes need to stay clear.
Related Research Directions
Compounds often discussed alongside MK-677: ipamorelin, cjc-1295, sermorelin.
Related Research Compounds
If you're researching MK-677, the compounds you'll likely want to look at next are: Ipamorelin, CJC-1295, SERMORELIN. These appear most often in the same research contexts as alternatives or complementary compounds.
References and Regulatory Notes
This guide synthesizes published research literature on MK-677. Specific citations are referenced inline where relevant. Research-compound regulatory status varies by jurisdiction; most are not approved by the FDA or equivalent agencies for human use and should be used only in research contexts compliant with applicable ethical review and regulations. This content is for research reference purposes only and does not constitute medical advice.
What Are the Practical Considerations for Using MK-677?
Practical implementation of any MK-677 protocol requires attention to several logistical factors that can significantly impact both convenience and outcomes. Storage conditions, preparation methods, and administration timing all contribute to the overall effectiveness of the protocol. Understanding these practical elements helps researchers establish consistent, reliable routines that maximize the potential benefits while minimizing waste and error.
Cost-effectiveness is another important practical consideration, as MK-677 protocols can represent a significant financial commitment over time. Evaluating different suppliers, comparing purity certificates, and calculating per-dose costs helps researchers make informed decisions about sourcing. Many experienced users recommend starting with smaller quantities to assess individual response before committing to bulk purchases, as this approach reduces financial risk while allowing for protocol optimization.
Documentation and tracking form the foundation of any well-designed research protocol. Maintaining detailed logs of dosage, timing, subjective effects, and any measurable biomarkers creates a valuable dataset for evaluating progress and making informed adjustments. Digital tracking tools and spreadsheets can simplify this process and help identify patterns that might not be apparent from memory alone.
What Does the Long-Term Research Outlook Look Like for MK-677?
The long-term research landscape for MK-677 continues to evolve as new studies emerge and our understanding of the underlying mechanisms deepens. While current evidence provides a foundation for informed decision-making, many questions remain unanswered, particularly regarding extended use patterns and long-term safety profiles. Researchers should stay current with published literature and adjust their protocols as new data becomes available.
The growing interest in peptide research has attracted increased attention from both academic institutions and regulatory bodies. This dual attention creates both opportunities and challenges—more research funding and institutional support on one hand, and potentially tighter regulatory frameworks on the other. Understanding the regulatory trajectory helps researchers plan their protocols within appropriate legal and ethical boundaries.
Community knowledge sharing plays an increasingly important role in advancing understanding of MK-677 applications. Online forums, research communities, and peer-reviewed case reports provide supplementary data that, while not meeting the gold standard of randomized controlled trials, offers valuable real-world context for protocol design and expectation setting.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).